<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26466073</article-id>
      <article-id pub-id-type="pmc">4592181</article-id>
      <article-id pub-id-type="doi">10.5935/abc.20150111</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Anabolic Drugs and Myocardial Infarction &#x2013; A Clinical Case
Report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>Rui Pontes</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pereira</surname>
            <given-names>Adriana</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guedes</surname>
            <given-names>Henrique</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Louren&#xE7;o</surname>
            <given-names>Carolina</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Azevedo</surname>
            <given-names>Jo&#xE3;o</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pinto</surname>
            <given-names>Paula</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">Servi&#xE7;o de Cardiologia, Centro Hospitalar T&#xE2;mega e Sousa, Penafiel &#x2013;
Portugal</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing Address: Rui Pontes Santos</bold>, Centro Hospitalar
T&#xE2;mega e Sousa. Centro Hospitalar T&#xE2;mega e Sousa, Lugar do Tapadinho, Guilhufe.
Postal Code 4564-007, Penafiel &#x2013; Portugal. E-mail:
<email>rui.pontes.santos@gmail.com</email></corresp>
        <fn fn-type="con">
          <p>
            <bold>Author contributions</bold>
          </p>
          <p>Acquisition of data: Santos RP, Pereira A, Guedes H. Analysis and interpretation
of the data: Santos RP, Pereira A, Guedes H. Writing of the manuscript: Santos RP,
Louren&#xE7;o C. Critical revision of the manuscript for intellectual content: Santos
RP, Louren&#xE7;o C, Azevedo J, Pinto P.</p>
        </fn>
        <fn fn-type="conflict">
          <p>
            <bold>Potential Conflict of Interest</bold>
          </p>
          <p>No potential conflict of interest relevant to this article was reported.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>9</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>9</month>
        <year>2015</year>
      </pub-date>
      <volume>105</volume>
      <issue>3</issue>
      <fpage>316</fpage>
      <lpage>319</lpage>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>12</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>11</day>
          <month>1</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>12</day>
          <month>1</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p>
        </license>
      </permissions>
      <kwd-group>
        <kwd>Anabolic Agents/adverse effects</kwd>
        <kwd>Human Growth Hormone</kwd>
        <kwd>Myocardial Infarction</kwd>
        <kwd>Heart Failure</kwd>
        <kwd>Clembuterol</kwd>
        <kwd>Weight Lifting</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>In most cases of myocardial infarction (MI) in young people, traditional cardiovascular
risk factors continue to be of utmost importance; but at this age, other causes should
also be considered, such as drug abuse.</p>
      <p>Anabolic steroids are synthetic derivatives of testosterone and are often illegally used
by athletes to increase their physical performance. There is a correlation between the
use of these drugs and increased cardiovascular risk<sup><xref rid="r01" ref-type="bibr">1</xref></sup>. Human growth hormone (hGH) has also been used to increase
physical performance, despite the risk of cardiovascular complications<sup><xref rid="r02" ref-type="bibr">2</xref></sup>. Clenbuterol is a potent &#x3B2;2-agonist that
also has anabolic effects. However, at present, little is known about its potential
cardiovascular risk<sup><xref rid="r03" ref-type="bibr">3</xref></sup>.</p>
      <p>Despite reports of MI associated with the use of anabolic steroids, no previous studies
have reported the simultaneous use of these three types of medications.</p>
    </sec>
    <sec>
      <title>Case Report</title>
      <p>A 25-year-old Caucasian male had no cardiovascular risk factors or history of other
known relevant diseases. His practiced bodybuilding and regularly consumed anabolic
steroids, hGH, and clenbuterol for the past 6 months. The last cycle, initiated 6 weeks
before the episode described herein, comprised the following: oxandrolone, 40 mg/day
(daily); clenbuterol, 0.08 mg/day (daily); mesterolone, 50 mg/day (daily); hGH, 10
IU/day (daily); nandrolone, 600 mg/day (twice a week); testosterone cypionate, 400
mg/day (twice a week); stanozolol, 100 mg/day (thrice a week); drostanolone, 200 mg/day
(thrice a week); trenbolone at 200 mg/day (thrice a week); testosterone propionate, 100
mg/day (thrice a week); boldenone, 400 mg/day (twice a week); and methenolone, 200
mg/day (twice a week). The patient denied having smoked or used any other drugs.</p>
      <p>The patient complained of intense oppressive retrosternal pain , without irradiation or
other accompanying symptoms; the pain lasted approximately 2 hours and was associated
with muscle fatigue after training. Approximately 24 hours after the initial episode,
the patient experienced recurrence of the pain, which worsened with inspiration
(different from the initial pain); he was therefore referred to emergency care.</p>
      <p>Upon admission to the emergency department, he was asymptomatic and physical examination
indicated hemodynamic stability and fever (38.4&#xBA;C) with no other significant findings.
The electrocardiogram (ECG) showed sinus rhythm, heart rate of 83 beats/minute, with
signs of infarction on the inferior and posterior walls of the left ventricle (LV) in
the subacute phase (<xref ref-type="fig" rid="f01">Figure 1</xref>). Laboratory tests
showed increased levels of the following myocardial necrosis markers: CPK, 1987 IU/L
(reference value [RF] &lt; 172 IU/L); troponin I, 48.97 ng/mL (RF &lt; 0.05 ng/mL) on
admission, with subsequent tendency to decrease; BNP, 115 pg/mL (RF &lt; 100 pg/mL); and
CRP, 33.3 mg/L (RF &lt; 7.5 mg/L), with a maximum peak of 204.4 mg/L on admission. The
clotting factors were within normal limits. The patient was started on double platelet
antiaggregant therapy with acetylsalicylic acid and clopidogrel and anticoagulation
therapy with fondaparinux.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Electrocardiogram on admission with signs of infarction on the inferior and
posterior left ventricular walls in the subacute phase.</p>
        </caption>
        <graphic xlink:href="abc-105-03-0316-g01"/>
      </fig>
      <p>He was admitted to the cardiac intensive care unit with a diagnosis of MI with
ST-segment elevation of posteroinferior location in the subacute phase, of Killip
Kimball class I, associated with likely post-infarction pericarditis. Echocardiographic
examination indicated hypokinesia of the middle and basal segments of the inferior,
posterior, and lateral LV walls. Of note was the presence of mild concentric LV
hypertrophy and the preservation of the overall biventricular systolic function.</p>
      <p>Approximately 48 hours after the onset of symptoms, the patient underwent coronary
angiography, which indicated fusiform stenosis in the proximal third of the right
coronary artery, suggestive of intraluminal thrombus, but it did not represent a
significant stenosis condition (<xref ref-type="fig" rid="f02">Figure 2</xref>). He
showed no changes suggestive of atherosclerotic epicardial coronary disease. Owing to
the small size of the thrombus, it was decided to continue the anticoagulation therapy
until the end of hospitalization and prolong the double antiaggregant therapy with the
use of maintenance doses.</p>
      <fig id="f02" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Coronary angiography examination indicated intraluminal thrombus in the proximal
third of the right coronary artery.</p>
        </caption>
        <graphic xlink:href="abc-105-03-0316-g02"/>
      </fig>
      <p>During hospitalization, he presented a favorable outcome and remained electrically and
hemodynamically stable, without pain recurrence and with analytical improvement. Being
asymptomatic, he was discharged on the eighth day of hospitalization, with a
prescription of aspirin (150 mg od), clopidogrel (75 mg od), bisoprolol (5 mg od),
ramipril (2.5 mg od), and rosuvastatin (10 mg od).</p>
      <p>He initiated follow-up with a cardiology consultation. One year after hospital
discharge, he remained abstinent from anabolic substances and was asymptomatic from the
cardiovascular point of view. ECG and echocardiography examination performed at the last
follow-up maintained the changes described previously. In addition, a stress test was
conducted, which indicated no changes suggestive of MI.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Although uncommon, some MI cases have been reported among young individuals without
cardiovascular risk factors and who use anabolic steroids<sup><xref rid="r04" ref-type="bibr">4</xref>-<xref rid="r07" ref-type="bibr">7</xref></sup>. Although this
cause-effect relationship is not fully understood, some hypotheses have been proposed to
explain the cardiovascular adverse effects of anabolic steroids<sup><xref rid="r08" ref-type="bibr">8</xref></sup>.</p>
      <p>Some studies attribute a thrombotic effect to anabolic steroids. These drugs appear to
be associated with increased platelet aggregation, as a result of the increased
production of thromboxane A2 and decreased production of prostacyclin. In addition,
changes in the coagulation cascade may occur, including increased thrombin activity,
which also contributes to a hypercoagulable state<sup><xref rid="r01" ref-type="bibr">1</xref></sup>. These adverse effects are exacerbated by dehydration and
catecholaminergic stress, which often occur in association with physical
activities<sup><xref rid="r08" ref-type="bibr">8</xref></sup>.</p>
      <p>hGH has also been associated with cardiovascular complications. hGH abuse contributes to
increased heart rate and cardiac output, consequently leading to concentric ventricular
hypertrophy and diastolic dysfunction; in certain patients, it may even promote
ischemia/necrosis and heart failure associated with impairment of the systolic
function<sup><xref rid="r02" ref-type="bibr">2</xref></sup>.</p>
      <p>Clenbuterol, when administered orally, appears to have anabolic effects, contributing to
an increase in muscle mass<sup><xref rid="r03" ref-type="bibr">3</xref></sup>. Despite
limited information about the potential cardiac complications, two cases of MI have been
reported in which clenbuterol may have had a key role<sup><xref rid="r09" ref-type="bibr">9</xref>-<xref rid="r10" ref-type="bibr">10</xref></sup>. It is
speculated that its positive chronotropic and inotropic effects, in addition to the
redistribution of coronary circulation, may promote myocardial ischemia<sup><xref rid="r08" ref-type="bibr">8</xref></sup>.</p>
      <p>Therefore, we believe that this patient suffered from an MI due to anabolic steroid
abuse and that it was a type 2 MI, in which intraluminal thrombus formation occurred due
to a hypercoagulable state associated with the use of anabolic steroids. In this case,
it is important to stress the possible synergistic effect of the concomitant use of hGH
and clenbuterol. It has been shown that both drugs promote myocardial ischemia, which
allows us to hypothesize that all three drugs may have contributed to the final clinical
outcome of this patient.</p>
      <p>In conclusion, the use of anabolic steroids seems to be a risk factor for the
development of acute coronary syndrome. This reinforces the idea that it is necessary to
exclude a previous history of consumption of illicit drugs in the presence of an MI,
particularly in patients with low cardiovascular risk.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>
          <bold>Sources of Funding</bold>
        </p>
        <p>There were no external funding sources for this study.</p>
      </fn>
      <fn fn-type="other">
        <p>
          <bold>Study Association</bold>
        </p>
        <p>This study is not associated with any thesis or dissertation work.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vanberg</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Atar</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Androgenic anabolic steroid abuse and the cardiovascular
system</article-title>
          <source>Handb Exp Pharmacol</source>
          <year>2010</year>
          <issue>195</issue>
          <fpage>411</fpage>
          <lpage>457</lpage>
          <pub-id pub-id-type="pmid">20020375</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holt</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>S&#xF6;nksen</surname>
              <given-names>PH</given-names>
            </name>
          </person-group>
          <article-title>Growth hormone, IGF-I and insulin and their abuse in
sport</article-title>
          <source>Br J Pharmacol</source>
          <year>2008</year>
          <volume>154</volume>
          <issue>3</issue>
          <fpage>542</fpage>
          <lpage>556</lpage>
          <pub-id pub-id-type="pmid">18376417</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Winter</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Effect of Clenbuterol on athletic performance</article-title>
          <source>Ann Pharmacother</source>
          <year>1995</year>
          <volume>29</volume>
          <issue>1</issue>
          <fpage>75</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="pmid">7711351</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ilhan</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Demirci</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>G&#xFC;ven&#xE7;</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Calik</surname>
              <given-names>AN</given-names>
            </name>
          </person-group>
          <article-title>Acute myocardial infarction and renal infarction in a bodybuilder
using anabolic steroids</article-title>
          <source>Turk Kardiyol Dern Ars</source>
          <year>2010</year>
          <volume>38</volume>
          <issue>4</issue>
          <fpage>275</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="pmid">20935436</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>G&#xFC;nes</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Erbas</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Okuyan</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Babalik</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>G&#xFC;rmen</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Myocardial infarction with intracoronary thrombus induced by anabolic
steroids</article-title>
          <source>Anadolu Kardiyol Derg</source>
          <year>2004</year>
          <volume>4</volume>
          <issue>4</issue>
          <fpage>357</fpage>
          <lpage>358</lpage>
          <pub-id pub-id-type="pmid">15590370</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stergiopoulos</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Brennan</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Mathews</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Setaro</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Kort</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Anabolic steroids, acute myocardial infarction and polycythemia: a
case report and review of the literature</article-title>
          <source>Vasc Health Risk Manag</source>
          <year>2008</year>
          <volume>4</volume>
          <issue>6</issue>
          <fpage>1475</fpage>
          <lpage>1480</lpage>
          <pub-id pub-id-type="pmid">19337562</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garg</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Sivananthan</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Intravascular ultrasound and angiographic demonstration of left main
stem thrombus-high-risk presentation in a young adult with anabolic steroid
abuse</article-title>
          <source>Am Heart Hosp J</source>
          <year>2010</year>
          <volume>8</volume>
          <issue>2</issue>
          <fpage>E125</fpage>
          <lpage>E127</lpage>
          <pub-id pub-id-type="pmid">21928180</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deligiannis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bj&#xF6;rnstad</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Carre</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Heidb&#xFC;chel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kouidi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Panhuyzen-Goedkoop</surname>
              <given-names>NM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ESC study group of sports cardiology position paper on adverse
cardiovascular effects of doping in athletes</article-title>
          <source>Eur J Cardiovasc Prev Rehabil</source>
          <year>2006</year>
          <volume>13</volume>
          <issue>5</issue>
          <fpage>687</fpage>
          <lpage>694</lpage>
          <pub-id pub-id-type="pmid">17001206</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goldstein</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Dobbs</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Krull</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Plumb</surname>
              <given-names>VJ</given-names>
            </name>
          </person-group>
          <article-title>Clembuterol and anabolic steroids: a previously unreported cause of
myocardial infarction with normal coronary arteriograms</article-title>
          <source>South Med J</source>
          <year>1998</year>
          <volume>9</volume>
          <issue>8</issue>
          <fpage>780</fpage>
          <lpage>784</lpage>
          <pub-id pub-id-type="pmid">9715231</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kierzkowska</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Stanczyk</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kasprzak</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Myocardial infarction in a 17-year-old body builder using
clenbuterol</article-title>
          <source>Circ J</source>
          <year>2005</year>
          <volume>69</volume>
          <issue>9</issue>
          <fpage>1144</fpage>
          <lpage>1146</lpage>
          <pub-id pub-id-type="pmid">16127201</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
